Genome editing and kidney health

Abstract

Genome editing technologies, CRISPR/Cas in particular, have revolutionized the field of genetic engineering, providing promising avenues for treating various genetic diseases. Chronic Kidney Disease (CKD), a significant health concern affecting millions of individuals worldwide, can arise from either monogenic or polygenic mutations. With recent advancements in genomic sequencing, valuable insights into disease-causing mutations can be obtained, allowing for the development of new treatments for these genetic disorders. CRISPR-based treatments have emerged as potential therapies, especially for monogenic diseases, offering the ability to correct mutations and eliminate disease phenotypes. Innovations in genome editing have led to enhanced efficiency, specificity, and ease of use, surpassing earlier editing tools such as zinc-finger nucleases and TALENs. Two prominent advancements in CRISPR-based gene editing are prime editing and base editing. Prime editing allows precise and efficient genome modifications without inducing double-stranded DNA breaks, while base editing enables targeted changes to individual nucleotides in both RNA and DNA, promising disease correction in absence of double strand DNA breaks (DSBs). These technologies have the potential to treat genetic kidney diseases through specific correction of disease-causing mutations, such as somatic mutations in PKD1 and PKD2 for polycystic kidney disease (PKD), NPHS1, NPHS2, and TRPC6 for Focal Segmental Glomerulosclerosis (FSGS), COL4A3, COL4A4, and COL4A5 for Alport Syndrome, SLC3A1 and SLC7A9 for Cystinuria, and even VHL for Renal Cell Carcinoma (RCC). Apart from editing DNA sequence, CRISPR-mediated epigenome editing offers a cost-effective method for targeted treatment providing new avenues for therapeutic development given that epigenetic modifications are associated with the development of various kidney disorders. However, there are challenges to overcome, these include developing efficient delivery methods, improving safety, and reducing off-target effects. Efforts to improve CRISPR/Cas technologies involve optimizing delivery vectors, employing viral and non-viral approaches, and minimizing immunogenicity. With research in animal models providing promising results in rescuing the expression of wild type podocin in mouse models of nephrotic syndrome, and successful clinical trials in the early stages of various disorders, including cancer immunotherapy, there is hope for successful translation of genome editing to kidney diseases.